Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

29 September 2023

Generic makers fall short when providing access to low- and middle-income countries, analysis finds

For STAT, Ed Silverman writes about the first report from the Foundation's Generic & Biosimilar Medicines Programme. The article kicks off with a statistic from the report showing that just one of 50 products marketed by the five generic drug companies in scope has a pricing strategy that considers patients' ability to pay. This has huge consequences for those living in low- and middle-income countries (LMICs), who often have to pay out of their own pocket.

Direct links

Read the article

The article looks at the potential for generic and biosimilar companies to do so much more to expand access, and how the report identifies where they're falling short.

The Foundation's CEO, Jayasree Iyer, is quoted: “Today, the generics industry focuses mainly still on their domestic market and the U.S. and Europe, while there are many opportunities worldwide. So they are feeling the pressures, too, like the big research-based companies. (These) companies need to go from the transactional tender-based mechanisms and complement that with much more effort to reach underserved populations, and be more transparent about their actions.”

Read the Foundation's report on generic and biosimilar medicine manufacturers.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved